Immunoscore Refines CRC Prognosis, Therapy
-
By
January 7, 2026
-
4 min
-
1
Immunoscore predicts outcomes better than TNM staging in colorectal cancer.
-
2
Key focus is on CD3+ and CD8+ T-cell densities.
-
3
High Immunoscore patients benefit from chemotherapy.
-
4
Low Immunoscore patients show limited chemotherapy benefit.
-
5
Technical and cost barriers hinder Immunoscore implementation.
-
6
The need for standardized training is critical.
-
7
Prospective validation across diverse tumors is crucial for wider adoption.
-
The Immunoscore emerges as a superior method for predicting outcomes in colorectal cancer, exceeding traditional TNM staging by accurately identifying high-risk patients who could benefit from enhanced chemotherapy. Developed by researchers at The University of Hong Kong, the Immunoscore evaluates immune response through T-cell density in tumors. Despite large-scale validation proving its efficacy, its implementation in clinical practice is hindered by technical and cost-related barriers. The authors stress the need for its integration into standard care to improve patient treatment strategies.
-
1
Immunoscore predicts outcomes better than TNM staging in colorectal cancer.
-
2
Key focus is on CD3+ and CD8+ T-cell densities.
-
3
High Immunoscore patients benefit from chemotherapy.
-
4
Low Immunoscore patients show limited chemotherapy benefit.
-
5
Technical and cost barriers hinder Immunoscore implementation.
-
6
The need for standardized training is critical.
-
7
Prospective validation across diverse tumors is crucial for wider adoption.
Listen Tab content
